Mirador Capital Partners LP Raises Holdings in LifeMD, Inc. (NASDAQ:LFMD)

Mirador Capital Partners LP lifted its stake in LifeMD, Inc. (NASDAQ:LFMD) by 139.3% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 106,059 shares of the company’s stock after purchasing an additional 61,731 shares during the quarter. Mirador Capital Partners LP’s holdings in LifeMD were worth $525,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of LFMD. Quest Partners LLC acquired a new stake in LifeMD during the 2nd quarter worth about $31,000. nVerses Capital LLC acquired a new position in LifeMD in the 3rd quarter worth approximately $46,000. Intech Investment Management LLC acquired a new stake in LifeMD during the 3rd quarter valued at approximately $54,000. CWM LLC purchased a new stake in shares of LifeMD in the 3rd quarter valued at $59,000. Finally, SG Americas Securities LLC purchased a new position in shares of LifeMD during the third quarter worth $70,000. 35.52% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

LFMD has been the subject of a number of recent research reports. KeyCorp reduced their price objective on LifeMD from $10.00 to $7.00 and set an “overweight” rating for the company in a research note on Wednesday, January 8th. HC Wainwright reaffirmed a “buy” rating and set a $12.00 price objective on shares of LifeMD in a research note on Monday, November 11th. Mizuho started coverage on shares of LifeMD in a report on Wednesday, December 4th. They issued a “neutral” rating and a $7.00 price objective for the company. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $15.00 price target on shares of LifeMD in a report on Friday, September 20th. Finally, Lake Street Capital began coverage on LifeMD in a report on Tuesday, December 10th. They issued a “buy” rating and a $12.00 price objective on the stock. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $11.14.

LifeMD Stock Performance

LifeMD stock opened at $4.91 on Thursday. LifeMD, Inc. has a 1 year low of $3.99 and a 1 year high of $12.88. The company’s 50 day simple moving average is $5.62 and its 200-day simple moving average is $5.49. The company has a market capitalization of $212.65 million, a price-to-earnings ratio of -7.67 and a beta of 1.49.

Insider Transactions at LifeMD

In other LifeMD news, CEO Justin Schreiber sold 25,000 shares of the stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $5.19, for a total transaction of $129,750.00. Following the sale, the chief executive officer now directly owns 2,703,715 shares in the company, valued at $14,032,280.85. This represents a 0.92 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 15.97% of the company’s stock.

LifeMD Company Profile

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.